Bionor Pharma ASA announced that the clinical trial application for the placebo-controlled study with Vacc-4x in combination with Celgene's (CELG) Revlimid has been approved by the German health regulatory authorities.
The study will be conducted at four different clinics in Germany, and will include HIV patients who do not recover a normal CD4 T-cell count despite receiving conventional HIV medicine.
The two main objectives of the study are to investigate the ability of Vacc-4x to improve the CD4 T-cell count in patients who have failed to regain these T helper cell counts to nearly normal levels despite well controlled viral load on ART, and to investigate whether Revlimid can further enhance the immune stimulating effect of Vacc-4x.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.